This review topic covers mechanisms that stabilize HIF-1 under normoxic conditions and allow adaptive gene activation. It emphasizes that HIF-1 activity can occur even when oxygen is not limiting.
First-pass extracted concept
HIF-1 stabilization under normoxic conditions
Candidate: concept label1 source documents5 linked claims
Live refresh every 5sNext refresh in 5s
Aliases
HIF-1 stability under normoxia, normoxic HIF-1 stabilization
Extracted Explainers
What the tool is doing
What problem it solves
What it does not solve
Evidence Snippets
Supporting Sources
Linked Claims
HIF-1 is extensively involved in cancer and cardiovascular diseases and may link these disease areas.
Quoted textsource-backed
HIF-1 is extensively involved in cancer and cardiovascular diseases and potentially serves as a bridge between them
HIF-1α can sometimes remain active in normoxia by translocating to the nucleus, dimerizing with HIF-1β, and activating genes involved in angiogenesis, metabolic reprogramming, and cellular survival.
Quoted textsource-backed
sometimes even in normoxia, HIF-1α translocates into the nucleus, dimerizes with HIF-1β to generate HIF-1, and then activates genes involved in adaptive responses such as angiogenesis, metabolic reprogramming, and cellular survival
Under normoxic conditions, HIF-1α is usually hydroxylated by prolyl hydroxylase domain enzymes, leading to ubiquitination and proteasomal degradation and thereby maintaining low HIF-1α levels.
Quoted textsource-backed
HIF-1α, as an unstable subunit of HIF-1, is usually hydroxylated by prolyl hydroxylase domain enzymes under normoxic conditions, leading to ubiquitination and proteasomal degradation, thereby keeping low levels.
The review covers transcriptional, translational, and posttranslational mechanisms that maintain HIF-1 stability under normoxia.
Quoted textsource-backed
the review delves into the mechanisms by which HIF-1 maintains its stability under normoxia including but not limited to giving insights into transcriptional, translational, as well as posttranslational regulation
The review summarizes HIF-1-related drugs that are approved or in clinical trials and highlights their potential for targeting HIF-1 in cancer and cardiovascular toxicity related to cancer treatment.
Quoted textsource-backed
An overview of HIF-1-related drugs that are approved or in clinical trials is summarized, highlighting their potential capacity for targeting HIF-1 in cancer and cardiovascular toxicity related to cancer treatment.